MX394736B - Agonistas del receptor glp-1 y usos de los mismos. - Google Patents
Agonistas del receptor glp-1 y usos de los mismos.Info
- Publication number
- MX394736B MX394736B MX2020013624A MX2020013624A MX394736B MX 394736 B MX394736 B MX 394736B MX 2020013624 A MX2020013624 A MX 2020013624A MX 2020013624 A MX2020013624 A MX 2020013624A MX 394736 B MX394736 B MX 394736B
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- receptor agonists
- aza
- benzimidazoles
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
Abstract
Se proporcionan en la presente ácidos 6-carboxílicos de bencimidazoles y 4-aza-, 5-aza-, y 7-aza-bencimidazoles como agonistas de GLP-1R, procesos para elaborar tales compuestos y métodos que comprenden administrar tales compuestos a un mamífero en necesidad del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685656P | 2018-06-15 | 2018-06-15 | |
| PCT/IB2019/054961 WO2019239371A1 (en) | 2018-06-15 | 2019-06-13 | Glp-1 receptor agonists and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020013624A MX2020013624A (es) | 2022-08-11 |
| MX394736B true MX394736B (es) | 2025-03-24 |
Family
ID=67766191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013624A MX394736B (es) | 2018-06-15 | 2019-06-13 | Agonistas del receptor glp-1 y usos de los mismos. |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11858916B2 (es) |
| EP (1) | EP3806855B1 (es) |
| JP (1) | JP7053900B2 (es) |
| KR (1) | KR102538572B1 (es) |
| CN (1) | CN112566637B (es) |
| AU (1) | AU2019285570B2 (es) |
| BR (1) | BR112020024956A2 (es) |
| CA (1) | CA3103051C (es) |
| DK (1) | DK3806855T5 (es) |
| ES (1) | ES2943510T3 (es) |
| FI (1) | FI3806855T3 (es) |
| HU (1) | HUE061888T2 (es) |
| IL (1) | IL279224B2 (es) |
| MX (1) | MX394736B (es) |
| PL (1) | PL3806855T3 (es) |
| PT (1) | PT3806855T (es) |
| RU (1) | RU2765721C1 (es) |
| SG (1) | SG11202011704XA (es) |
| SI (1) | SI3806855T1 (es) |
| WO (1) | WO2019239371A1 (es) |
| ZA (1) | ZA202007304B (es) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3806855T3 (fi) * | 2018-06-15 | 2023-05-04 | Pfizer | Glp-1 -reseptorin agonisteja ja niiden käyttöjä |
| EA202191432A1 (ru) | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
| AU2020256647B2 (en) * | 2019-04-12 | 2025-07-31 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| WO2021018023A1 (zh) * | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| CR20220178A (es) | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| EP4073051B1 (en) | 2019-12-10 | 2024-02-07 | Eli Lilly and Company | Process and intermediate for the preparation of oxetan-2-ylmethanamine |
| SI4097097T1 (sl) | 2020-01-29 | 2025-04-30 | Gilead Sciences, Inc. | Spojine, ki modulirajo glp-1r |
| PT4097099T (pt) | 2020-02-07 | 2024-07-19 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| CN115697999A (zh) * | 2020-02-13 | 2023-02-03 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| KR102563111B1 (ko) * | 2020-03-18 | 2023-08-04 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| MX2022011349A (es) * | 2020-03-18 | 2022-11-10 | Lg Chemical Ltd | Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo. |
| CN113493447B (zh) * | 2020-04-03 | 2024-06-11 | 轩竹(北京)医药科技有限公司 | Glp-1受体激动剂 |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| CA3171950A1 (en) * | 2020-04-22 | 2021-10-28 | David William Sheppard | Collagen 1 translation inhibitors and methods of use thereof |
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| PH12022553313A1 (en) * | 2020-06-04 | 2023-04-12 | Hangzhou Sciwind Biosciences Co Ltd | Five-membered heteroaromatic imidazole compound and use thereof |
| US12637474B2 (en) | 2020-06-04 | 2026-05-26 | Hangzhou Sciwind Biosciences Co., Ltd | Five-membered heteroaromatic imidazole compound and use thereof |
| WO2021249492A1 (zh) * | 2020-06-10 | 2021-12-16 | 南京明德新药研发有限公司 | 甲基取代的苯并二噁唑类化合物及其应用 |
| TW202214610A (zh) * | 2020-06-19 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 6-側氧-3,6-二氫吡啶類衍生物、其製備方法及其在醫藥上的應用 |
| CN113816948B (zh) * | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| WO2021259309A1 (zh) * | 2020-06-24 | 2021-12-30 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| JP2023538408A (ja) * | 2020-08-21 | 2023-09-07 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | Glp-1r作動薬としての化合物 |
| JP2023538949A (ja) | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
| WO2022052958A1 (en) | 2020-09-10 | 2022-03-17 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN115515956B (zh) * | 2020-09-29 | 2024-06-25 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| WO2022078380A1 (en) * | 2020-10-13 | 2022-04-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2023546055A (ja) * | 2020-10-13 | 2023-11-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
| US12516041B2 (en) | 2020-10-14 | 2026-01-06 | Qilu Regor Therapeutics Inc. | Crystal forms of GLP-1R agonists and uses thereof |
| CN114478497B (zh) * | 2020-11-12 | 2023-10-20 | 杭州中美华东制药有限公司 | 芳基烷基酸类glp-1受体激动剂及其用途 |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| WO2022111624A1 (zh) | 2020-11-27 | 2022-06-02 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| CN114591308B (zh) * | 2020-12-03 | 2024-03-08 | 苏州闻泰医药科技有限公司 | 一类glp-1r受体激动剂化合物及其用途 |
| CN114805336B (zh) * | 2021-01-20 | 2026-04-14 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类化合物、其制备方法及其在医药上的应用 |
| WO2022184849A1 (en) | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US12180197B2 (en) | 2021-03-11 | 2024-12-31 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| EP4317145A4 (en) | 2021-03-24 | 2025-03-12 | Shionogi & Co., Ltd | Pharmaceutical composition containing glp-1 receptor agonist having fused ring |
| US20240300928A1 (en) * | 2021-04-08 | 2024-09-12 | Lg Chem, Ltd. | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| EP4582421A3 (en) * | 2021-04-08 | 2025-10-01 | LG Chem, Ltd. | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| LT4271672T (lt) | 2021-04-21 | 2026-03-10 | Gilead Sciences, Inc. | Karboksibenzimidazolo junginiai, moduliuojantys glp-1r |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| US20240382471A1 (en) * | 2021-07-21 | 2024-11-21 | Hepagene Therapeutics (HK) Limited | Glucagon-like peptide-1 receptor modulators and uses thereof |
| CN113480534B (zh) * | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| TW202321240A (zh) * | 2021-08-02 | 2023-06-01 | 大陸商深圳信立泰藥業股份有限公司 | Glp-1r促效劑化合物的鹽、包括其的藥物組合物及其用途 |
| US20240360109A1 (en) * | 2021-08-04 | 2024-10-31 | Shanghai Hansoh Biomedical Co., Ltd. | Cycloalkene derivative regulator, preparation method therefor, and application thereof |
| KR20240053617A (ko) | 2021-08-30 | 2024-04-24 | 민드랭크 에이아이 리미티드 | Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물 |
| KR20240056719A (ko) | 2021-09-08 | 2024-04-30 | 시오노기 앤드 컴파니, 리미티드 | 항비만 작용이 관여하는 질환의 예방 및 치료용 의약 |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057427A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| US20250236627A1 (en) | 2021-10-05 | 2025-07-24 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| TWI843243B (zh) * | 2021-10-22 | 2024-05-21 | 大陸商盛世泰科生物醫藥技術(蘇州)股份有限公司 | 作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途 |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| CN115850296B (zh) * | 2021-12-03 | 2025-03-11 | 杭州先为达生物科技股份有限公司 | 一种噻吩并咪唑类化合物的晶型及其制备方法 |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| CN118613476A (zh) * | 2022-01-10 | 2024-09-06 | 西藏海思科制药有限公司 | 一种glp-1激动剂盐及其晶型及在医药上的应用 |
| WO2023138684A1 (en) * | 2022-01-24 | 2023-07-27 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
| AU2023224854A1 (en) | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| AU2023232184A1 (en) * | 2022-03-08 | 2024-09-26 | Guangzhou Apichope Pharmaceutical Co., Ltd. | Benzo bicyclic compound, and preparation method and application thereof |
| CN120289449A (zh) * | 2022-07-18 | 2025-07-11 | 厦门市博瑞来医药科技有限公司 | 一种合成非甾体类fxr调节剂的化合物 |
| CN119923395A (zh) * | 2022-07-27 | 2025-05-02 | 卡莫特医疗有限公司 | N-杂环gpcr受体激动剂、包含其的药物组合物和其使用方法 |
| CN119907794A (zh) | 2022-09-22 | 2025-04-29 | 盐野义制药株式会社 | 具有glp-1受体激动剂作用的稠环化合物 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| CR20250178A (es) | 2022-11-16 | 2025-06-06 | Lilly Co Eli | Agonistas del receptor del péptido-1 similar al glucagón |
| AU2023394509A1 (en) * | 2022-12-13 | 2025-07-10 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Salt-type glp-1 receptor agonist, crystal form thereof, preparation method therefor, pharmaceutical composition thereof, and use thereof |
| CN116082321B (zh) * | 2022-12-23 | 2026-05-05 | 华中药业股份有限公司 | 一种咪唑并芳杂基类衍生物、药物组合物及其应用 |
| CN118344349A (zh) * | 2023-01-13 | 2024-07-16 | 中国科学院上海药物研究所 | 用作glp-1受体激动剂的4-烷氧基苯并咪唑-6-羧酸衍生物 |
| KR20250168210A (ko) | 2023-02-16 | 2025-12-02 | 가셔브룸 바이오, 인크. | 헤테로시클릭 glp-1 효능제 |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| CN121311466A (zh) | 2023-04-14 | 2026-01-09 | 辉瑞大药厂 | 葡萄糖依赖性促胰岛素多肽受体拮抗剂及其用途 |
| JP2026526054A (ja) | 2023-07-13 | 2026-08-04 | アコンカグア・バイオ・インコーポレイテッド | 化合物、組成物、および方法 |
| EP4743174A1 (en) | 2023-07-13 | 2026-05-20 | Aconcagua Bio, Inc. | CALCITONIN AND/OR AMYLIN RECEPTOR ACTIVITY MODULATORS |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| US20250163168A1 (en) | 2023-11-17 | 2025-05-22 | Pfizer Inc. | Novel antibodies and antibody conjugates for the treatment of metabolic disorders |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| TW202539633A (zh) | 2024-02-01 | 2025-10-16 | 美商輝瑞股份有限公司 | 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途 |
| WO2025171340A1 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | The treatment of calcitonin- and/or amylin-receptor associated conditions |
| WO2025171341A2 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| WO2025208093A1 (en) * | 2024-03-28 | 2025-10-02 | Gila Therapeutics, Inc. | Compositions and methods for treating metabolic diseases with topical-lingual receptor agonists |
| WO2025224599A1 (en) | 2024-04-22 | 2025-10-30 | Pfizer Inc. | Pyrrolidine-based glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026013531A1 (en) | 2024-07-10 | 2026-01-15 | Pfizer Inc. | Spiro[2.5]octane compounds |
| WO2026033382A1 (en) | 2024-08-07 | 2026-02-12 | Pfizer Inc. | Heterocyclic glp-1r modulators |
| WO2026042018A1 (en) | 2024-08-21 | 2026-02-26 | Pfizer Inc. | 4-{4-[(1-{[4-(propan-2-yl)phenyl]carbamoyl)-d-prolyl)amino]cyclohexyl}benzoic acid derivatives as gipr antagonists for the treatment of diabetes |
| WO2026051998A1 (en) | 2024-09-04 | 2026-03-12 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
| WO2026078617A1 (en) | 2024-10-11 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078673A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078672A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078671A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic compounds as glucose-dependent insulinotropic polypeptide receptor antagonists |
| WO2026078670A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists |
| WO2026078674A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026088071A1 (en) | 2024-10-23 | 2026-04-30 | Pfizer Inc. | Substituted fused heteroaryl lactam compounds |
| WO2026096926A1 (en) | 2024-11-01 | 2026-05-07 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
| CN119176808B (zh) * | 2024-11-25 | 2025-12-26 | 山东法恩新材料科技有限公司 | 一种glp-1激动剂及其制备方法和应用 |
| WO2026132278A2 (en) | 2024-12-20 | 2026-06-25 | F. Hoffmann-La Roche Ag | Process for the preparation of oxetane derivatives |
| WO2026156091A1 (en) | 2025-01-15 | 2026-07-23 | Aconcagua Bio, Inc. | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity |
| WO2026154417A1 (en) | 2025-01-17 | 2026-07-23 | Pfizer Inc. | Fused heterocyclic amide/sulfonamide compounds as agonists of the calcitonin/amylin receptors for the treatment of obesity |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US20040127504A1 (en) | 2002-09-06 | 2004-07-01 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| HRP20070241T3 (hr) * | 2003-12-19 | 2007-07-31 | Bristol-Myers Squibb Company | Azabiciklički heterocikli kao modulatori kanabinoid receptora |
| WO2007115077A2 (en) | 2006-03-31 | 2007-10-11 | Astrazeneca Ab | Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators |
| CN103221404B (zh) * | 2010-05-13 | 2015-12-16 | 安姆根有限公司 | 可用作pde10抑制剂的不饱和氮杂环化合物 |
| LT2897939T (lt) * | 2012-09-21 | 2017-05-10 | Sanofi | Benzimidazolo karboksirūgšties amido dariniai metabolinių arba širdies ir kraujagyslių ligų gydymui |
| WO2018109607A1 (en) | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CA3045644C (en) | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| FI3806855T3 (fi) * | 2018-06-15 | 2023-05-04 | Pfizer | Glp-1 -reseptorin agonisteja ja niiden käyttöjä |
| EA202191432A1 (ru) * | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
-
2019
- 2019-06-13 FI FIEP19759027.6T patent/FI3806855T3/fi active
- 2019-06-13 PT PT197590276T patent/PT3806855T/pt unknown
- 2019-06-13 MX MX2020013624A patent/MX394736B/es unknown
- 2019-06-13 RU RU2020141022A patent/RU2765721C1/ru active
- 2019-06-13 WO PCT/IB2019/054961 patent/WO2019239371A1/en not_active Ceased
- 2019-06-13 DK DK19759027.6T patent/DK3806855T5/da active
- 2019-06-13 JP JP2020569823A patent/JP7053900B2/ja active Active
- 2019-06-13 EP EP19759027.6A patent/EP3806855B1/en active Active
- 2019-06-13 BR BR112020024956-4A patent/BR112020024956A2/pt unknown
- 2019-06-13 PL PL19759027.6T patent/PL3806855T3/pl unknown
- 2019-06-13 SI SI201930518T patent/SI3806855T1/sl unknown
- 2019-06-13 KR KR1020217000887A patent/KR102538572B1/ko active Active
- 2019-06-13 US US17/251,929 patent/US11858916B2/en active Active
- 2019-06-13 CN CN201980053998.2A patent/CN112566637B/zh active Active
- 2019-06-13 AU AU2019285570A patent/AU2019285570B2/en active Active
- 2019-06-13 CA CA3103051A patent/CA3103051C/en active Active
- 2019-06-13 ES ES19759027T patent/ES2943510T3/es active Active
- 2019-06-13 SG SG11202011704XA patent/SG11202011704XA/en unknown
- 2019-06-13 HU HUE19759027A patent/HUE061888T2/hu unknown
-
2020
- 2020-11-24 ZA ZA2020/07304A patent/ZA202007304B/en unknown
- 2020-12-06 IL IL279224A patent/IL279224B2/en unknown
-
2023
- 2023-11-20 US US18/513,752 patent/US12331041B2/en active Active
-
2025
- 2025-05-15 US US19/209,381 patent/US20250270196A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013625A (es) | Agonistas del receptor de glp-1 y usos de los mismos. | |
| MX2020013624A (es) | Agonistas del receptor glp-1 y usos de los mismos. | |
| CO2019006046A2 (es) | Agonistas receptores de glp-1 y usos de los mismos | |
| CL2020000422A1 (es) | Composiciones de glp-1 y sus usos. | |
| DOP2025000199A (es) | Agonistas heterocíclicos de glp-1 | |
| CL2017001760A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
| CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
| AR102712A1 (es) | Agonistas parciales del receptor de insulina | |
| MX377384B (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer. | |
| UY35023A (es) | Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso | |
| UY36118A (es) | Compuestos y composiciones para inducir condrogénesis | |
| MX2020004855A (es) | Metodos utiles en la sintesis de analogos de halicondrina b. | |
| ECSP14002542A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 | |
| CL2012003642A1 (es) | Metodo para mejorar los rasgos relacionados con el rendimiento en plantas que comprende modular la expresion de osrsz33rrm; constructo que comprende osrsz33 rrm; uso del constructo para producir plantas que tienen mayor rendimiento. | |
| CL2016002469A1 (es) | Sulfamidasa modificada y su producción | |
| AR114080A1 (es) | Anticuerpos pac1 y sus usos | |
| EA202092674A1 (ru) | Агонисты рецептора glp-1 и их применение | |
| AR094379A1 (es) | ANTICUERPOS ANTI-PDGFR-b Y SUS USOS | |
| UY35662A (es) | Derivados de espiroindolina y composiciones farmacéuticas de los mismos | |
| AR093660A1 (es) | Proceso para la obtencion de bioetanol y carotenos a partir de zanahoria de descarte |